Drug intelligence / Profile preview

s-allylcysteine

Development stage
Phase 2
Modality
Small Molecules
Administration
Oral
01

Overview

S-allylcysteine is a water-soluble organosulfur compound derived from garlic (Allium sativum), most abundantly present in aged garlic extract. It is an amino acid derivative, chemically classed among the cysteine derivatives. S-allylcysteine exhibits antioxidant, anti-inflammatory, neuroprotective, cardioprotective, and potential antiglycative and antidepressant-like activities. Its mechanisms include (1) direct and indirect antioxidant action, restoring cellular antioxidant enzymes and decreasing lipid peroxidation, DNA fragmentation, and protein oxidation; (2) anti-amyloidogenic and antitangle activities relevant to neurodegenerative disease pathophysiology such as Alzheimer's disease; (3) reduction of inflammatory mediators; (4) inhibition of calpain activity through interaction with the Ca2+-binding site, resulting in reduced endoplasmic reticulum stress-induced neuronal death; (5) inhibition of aldose reductase preventing advanced glycation end products formation; (6) induction of the Nrf2 transcription factor pathway[1][3][5][7][9]. S-allylcysteine has been shown in preclinical models to mitigate oxidative stress, reduce proliferation and induce apoptosis in cancer cells, and exert antidepressant-like effects.

Other names
S-allyl cysteineS-allyl-L-cysteineL-cysteine, S-2-propenyl-2-amino-3-(prop-2-en-1-ylsulfanyl)propanoic aciddeoxyalliinL-deoxyalliinDL-S-allylcysteine(L)-3-(allylsulfenyl)-alanine(R)-allylthio-2-aminopropionic acid
02

Targets

AR (Adrenergic receptors)Cyp (Cyclophilin family)Amyloid fibrils

Beyond the preview

Go deeper on s-allylcysteine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on s-allylcysteine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call